Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Community-based HCV screening: knowledge and attitudes in a high risk urban population

Authors: Brianna L Norton, Corrine I Voils, Sarah H Timberlake, Emily J Hecker, Neela D Goswami, Kim M Huffman, Anneka Landgraf, Susanna Naggie, Jason E Stout

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

In an attempt to curtail the rising morbidity and mortality from undiagnosed HCV (hepatitis C virus) in the United States, screening guidelines have been expanded to high-risk individuals and persons born 1945–1965. Community-based screening may be one strategy in which to reach such persons; however, the acceptance of HCV testing, when many high-risk individuals may not have access to HCV specific medications, remains unknown.

Methods

We set out to assess attitudes about HCV screening and knowledge about HCV disease at several community-based testing sites that serve high-risk populations. This assessment was paired with a brief HCV educational intervention, followed by post-education evaluation.

Results

Participants (n = 140) were surveyed at five sites; two homeless shelters, two drug rehabilitation centers, and a women’s "drop-in" center. Personal acceptance of HCV testing was almost unanimous, and 90% of participants reported that they would still want to be tested even if they were unable to receive HCV treatment. Baseline hepatitis C knowledge was poor; however, the brief educational intervention significantly improved knowledge and increased acceptability of testing when medical access issues were explicitly stated.

Conclusions

Despite inconsistencies in access to care and treatment, high-risk communities want to know their HCV status. Though baseline HCV knowledge was poor in this population, a brief on-site educational intervention improved both knowledge and acceptability of HCV testing and care. These data support the establishment of programs that utilize community-based screening, and also provide initial evidence for acceptance of the implementation of the recently expanded screening guidelines among marginalized communities.
Literature
1.
go back to reference Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006, 144 (10): 705-714. 10.7326/0003-4819-144-10-200605160-00004.CrossRefPubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006, 144 (10): 705-714. 10.7326/0003-4819-144-10-200605160-00004.CrossRefPubMed
2.
go back to reference US Department of Health and Human Services: Combating the Silent Epidemic of Viral Hepatitis (Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis). 2011 US Department of Health and Human Services: Combating the Silent Epidemic of Viral Hepatitis (Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis). 2011
3.
go back to reference Verna EC, Brown RS: Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006, 10 (4): 919-940. 10.1016/j.cld.2006.08.012.CrossRefPubMed Verna EC, Brown RS: Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006, 10 (4): 919-940. 10.1016/j.cld.2006.08.012.CrossRefPubMed
4.
go back to reference Mitchell AE, Colvin HM, Palmer Beasley R: Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010, 51 (3): 729-733. 10.1002/hep.23561.CrossRefPubMed Mitchell AE, Colvin HM, Palmer Beasley R: Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010, 51 (3): 729-733. 10.1002/hep.23561.CrossRefPubMed
5.
go back to reference Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS: Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006, 121 (6): 710-719.PubMedPubMedCentral Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS: Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006, 121 (6): 710-719.PubMedPubMedCentral
6.
go back to reference Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012, 156 (4): 271-278. 10.7326/0003-4819-156-4-201202210-00004.CrossRefPubMed Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012, 156 (4): 271-278. 10.7326/0003-4819-156-4-201202210-00004.CrossRefPubMed
7.
go back to reference Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW: Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010, 138 (2): 513-521. 10.1053/j.gastro.2009.09.067. 521 e511-516CrossRefPubMed Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW: Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010, 138 (2): 513-521. 10.1053/j.gastro.2009.09.067. 521 e511-516CrossRefPubMed
8.
go back to reference Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB: Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011, 43 (1): 66-72. 10.1016/j.dld.2010.05.006.CrossRefPubMed Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB: Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011, 43 (1): 66-72. 10.1016/j.dld.2010.05.006.CrossRefPubMed
9.
go back to reference Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998, 47 (RR-19): 1-39. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998, 47 (RR-19): 1-39.
10.
go back to reference Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW: Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012, 157 (11): 817-822. 10.7326/0003-4819-157-9-201211060-00529.CrossRefPubMed Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW: Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012, 157 (11): 817-822. 10.7326/0003-4819-157-9-201211060-00529.CrossRefPubMed
11.
go back to reference Moyer VA: Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013 Moyer VA: Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013
12.
go back to reference Guerrero HJ GW, Fullmer C: A Novel Method of Reaching at-Risk Populations in Community Outreach Hepatitis Screening Programs. 2008, San Fransisco, CA: AASLD Guerrero HJ GW, Fullmer C: A Novel Method of Reaching at-Risk Populations in Community Outreach Hepatitis Screening Programs. 2008, San Fransisco, CA: AASLD
13.
go back to reference Subiadur J, Harris JL, Rietmeijer CA: Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. Public Health Rep. 2007, 122 (Suppl 2): 12-17.PubMedPubMedCentral Subiadur J, Harris JL, Rietmeijer CA: Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. Public Health Rep. 2007, 122 (Suppl 2): 12-17.PubMedPubMedCentral
14.
go back to reference Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS: Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis. 2001, 28 (3): 166-170. 10.1097/00007435-200103000-00008.CrossRefPubMed Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS: Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis. 2001, 28 (3): 166-170. 10.1097/00007435-200103000-00008.CrossRefPubMed
15.
go back to reference Hadley J, Cunningham P: Availability of safety net providers and access to care of uninsured persons. Health Serv Res. 2004, 39 (5): 1527-1546. 10.1111/j.1475-6773.2004.00302.x.CrossRefPubMedPubMedCentral Hadley J, Cunningham P: Availability of safety net providers and access to care of uninsured persons. Health Serv Res. 2004, 39 (5): 1527-1546. 10.1111/j.1475-6773.2004.00302.x.CrossRefPubMedPubMedCentral
16.
go back to reference Gunn RA, Murray PJ, Brennan CH, Callahan DB, Alter MJ, Margolis HS: Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project. Sex Transm Dis. 2003, 30 (4): 340-344. 10.1097/00007435-200304000-00013.CrossRefPubMed Gunn RA, Murray PJ, Brennan CH, Callahan DB, Alter MJ, Margolis HS: Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project. Sex Transm Dis. 2003, 30 (4): 340-344. 10.1097/00007435-200304000-00013.CrossRefPubMed
17.
go back to reference McCusker M: Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction. 2001, 96 (7): 1007-1014. 10.1046/j.1360-0443.2001.967100710.x.CrossRefPubMed McCusker M: Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction. 2001, 96 (7): 1007-1014. 10.1046/j.1360-0443.2001.967100710.x.CrossRefPubMed
18.
go back to reference Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML: Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics. 2010, 51 (2): 149-156. 10.1016/S0033-3182(10)70675-7.CrossRefPubMed Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML: Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics. 2010, 51 (2): 149-156. 10.1016/S0033-3182(10)70675-7.CrossRefPubMed
19.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49 (4): 1335-1374. 10.1002/hep.22759.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49 (4): 1335-1374. 10.1002/hep.22759.CrossRefPubMed
20.
go back to reference Zeuzem S: Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med. 2004, 140 (5): 370-381.PubMed Zeuzem S: Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med. 2004, 140 (5): 370-381.PubMed
21.
go back to reference Davis GL, Lau JY: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997, 26 (3 Suppl 1): 122S-127S.CrossRefPubMed Davis GL, Lau JY: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997, 26 (3 Suppl 1): 122S-127S.CrossRefPubMed
22.
go back to reference Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, et al: Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010, 53 (4): 616-623. 10.1016/j.jhep.2010.04.024.CrossRefPubMed Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, et al: Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010, 53 (4): 616-623. 10.1016/j.jhep.2010.04.024.CrossRefPubMed
23.
go back to reference Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, et al: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013, 368 (20): 1867-1877. 10.1056/NEJMoa1214854.CrossRefPubMed Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, et al: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013, 368 (20): 1867-1877. 10.1056/NEJMoa1214854.CrossRefPubMed
24.
go back to reference Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013, 368 (20): 1878-1887. 10.1056/NEJMoa1214853.CrossRefPubMed Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013, 368 (20): 1878-1887. 10.1056/NEJMoa1214853.CrossRefPubMed
25.
go back to reference Hunt D, Pockros P: What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?. Curr Gastroenterol Rep. 2013, 15 (1): 303-CrossRefPubMed Hunt D, Pockros P: What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?. Curr Gastroenterol Rep. 2013, 15 (1): 303-CrossRefPubMed
26.
go back to reference Litwin AH, Soloway I, Gourevitch MN: Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005, 40 (Suppl 5): S339-345.CrossRefPubMed Litwin AH, Soloway I, Gourevitch MN: Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005, 40 (Suppl 5): S339-345.CrossRefPubMed
27.
go back to reference Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN: Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012, 44 (6): 497-503. 10.1016/j.dld.2011.12.014.CrossRefPubMed Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN: Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012, 44 (6): 497-503. 10.1016/j.dld.2011.12.014.CrossRefPubMed
28.
go back to reference Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN: Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health. 2012, 102 (11): e115-121. 10.2105/AJPH.2012.300659.CrossRefPubMedPubMedCentral Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN: Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health. 2012, 102 (11): e115-121. 10.2105/AJPH.2012.300659.CrossRefPubMedPubMedCentral
29.
go back to reference Litwin AH, Harris KA, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH: Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009, 37 (1): 32-40.CrossRefPubMed Litwin AH, Harris KA, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH: Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009, 37 (1): 32-40.CrossRefPubMed
30.
go back to reference Proeschold-Bell RJ, Hoeppner B, Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ: An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. AIDS Behav. 2011, 15 (8): 1721-1731. 10.1007/s10461-010-9870-1.CrossRefPubMedPubMedCentral Proeschold-Bell RJ, Hoeppner B, Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ: An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. AIDS Behav. 2011, 15 (8): 1721-1731. 10.1007/s10461-010-9870-1.CrossRefPubMedPubMedCentral
31.
go back to reference O’Brien S, Day C, Black E, Dolan K: Injecting drug users’ understanding of hepatitis C. Addict Behav. 2008, 33 (12): 1602-1605. 10.1016/j.addbeh.2008.07.005.CrossRefPubMed O’Brien S, Day C, Black E, Dolan K: Injecting drug users’ understanding of hepatitis C. Addict Behav. 2008, 33 (12): 1602-1605. 10.1016/j.addbeh.2008.07.005.CrossRefPubMed
32.
go back to reference Proeschold-Bell RJ, Blouin R, Reif S, Amana A, Rowland BJ, Lombard F, Stringfield B, Muir AJ: Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. South Med J. 2010, 103 (7): 635-641. 10.1097/SMJ.0b013e3181e1dde1.CrossRefPubMed Proeschold-Bell RJ, Blouin R, Reif S, Amana A, Rowland BJ, Lombard F, Stringfield B, Muir AJ: Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. South Med J. 2010, 103 (7): 635-641. 10.1097/SMJ.0b013e3181e1dde1.CrossRefPubMed
33.
go back to reference Krauskopf K, McGinn TG, Federman AD, Halm EA, Leventhal H, McGinn LK, Gardenier D, Oster A, Kronish IM: HIV and HCV health beliefs in an inner-city community. J Viral Hepat. 2011, 18 (11): 785-791. 10.1111/j.1365-2893.2010.01383.x.CrossRefPubMed Krauskopf K, McGinn TG, Federman AD, Halm EA, Leventhal H, McGinn LK, Gardenier D, Oster A, Kronish IM: HIV and HCV health beliefs in an inner-city community. J Viral Hepat. 2011, 18 (11): 785-791. 10.1111/j.1365-2893.2010.01383.x.CrossRefPubMed
34.
go back to reference Treloar C, Hull P, Dore GJ, Grebely J: Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev. 2012, 31 (7): 918-924. 10.1111/j.1465-3362.2012.00468.x.CrossRefPubMed Treloar C, Hull P, Dore GJ, Grebely J: Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev. 2012, 31 (7): 918-924. 10.1111/j.1465-3362.2012.00468.x.CrossRefPubMed
35.
go back to reference Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL: Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008, 33 (3): 126-133. 10.1007/s10900-007-9083-3.CrossRefPubMedPubMedCentral Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL: Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008, 33 (3): 126-133. 10.1007/s10900-007-9083-3.CrossRefPubMedPubMedCentral
36.
go back to reference Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M: Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011, 56 (1): 213-219. 10.1007/s10620-010-1455-3.CrossRefPubMed Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M: Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011, 56 (1): 213-219. 10.1007/s10620-010-1455-3.CrossRefPubMed
37.
go back to reference Doab A, Treloar C, Dore GJ: Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis. 2005, 40 (Suppl 5): S313-320.CrossRefPubMed Doab A, Treloar C, Dore GJ: Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis. 2005, 40 (Suppl 5): S313-320.CrossRefPubMed
38.
go back to reference Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M: Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013, 33 (7): 999-1007. 10.1111/liv.12150.CrossRefPubMedPubMedCentral Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M: Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013, 33 (7): 999-1007. 10.1111/liv.12150.CrossRefPubMedPubMedCentral
39.
go back to reference Hawthorne K, Robles Y, Cannings-John R, Edwards AG: Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. Cochrane Database Syst Rev. 2008, 3: CD006424-PubMed Hawthorne K, Robles Y, Cannings-John R, Edwards AG: Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. Cochrane Database Syst Rev. 2008, 3: CD006424-PubMed
40.
go back to reference Kiene SM, Barta WD: A brief individualized computer-delivered sexual risk reduction intervention increases HIV/AIDS preventive behavior. J Adolesc Health. 2006, 39 (3): 404-410. 10.1016/j.jadohealth.2005.12.029.CrossRefPubMed Kiene SM, Barta WD: A brief individualized computer-delivered sexual risk reduction intervention increases HIV/AIDS preventive behavior. J Adolesc Health. 2006, 39 (3): 404-410. 10.1016/j.jadohealth.2005.12.029.CrossRefPubMed
Metadata
Title
Community-based HCV screening: knowledge and attitudes in a high risk urban population
Authors
Brianna L Norton
Corrine I Voils
Sarah H Timberlake
Emily J Hecker
Neela D Goswami
Kim M Huffman
Anneka Landgraf
Susanna Naggie
Jason E Stout
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-74

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue